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We have developed an automated, highly sensitive and specific method for identifying and enumerating circulating tumour cells
(CTCs) in the blood. Blood samples from 10 prostate, 25 colorectal and 4 ovarian cancer patients were analysed. Eleven healthy
donors and seven men with elevated serum prostate-specific antigen (PSA) levels but no evidence of malignancy served as controls.
Spiking experiments with cancer cell lines were performed to estimate recovery yield. Isolation was performed either by density
gradient centrifugation or by filtration, and the CTCs were labelled with monoclonal antibodies against cytokeratins 7/8 and either
AUA1 (against EpCam) or anti-PSA. The slides were analysed with the Ikoniscope
s robotic fluorescence microscope imaging system.
Spiking experiments showed that less than one epithelial cell per millilitre of blood could be detected, and that fluorescence in situ
hybridisation (FISH) could identify chromosomal abnormalities in these cells. No positive cells were detected in the 11 healthy
control samples. Circulating tumour cells were detected in 23 out of 25 colorectal, 10 out of 10 prostate and 4 out of 4 ovarian
cancer patients. Five samples (three colorectal and two ovarian) were analysed by FISH for chromosomes 7 and 8 combined and all
had significantly more than four dots per cell. We have demonstrated an Ikoniscope
s based relatively simple and rapid procedure for
the clear-cut identification of CTCs. The method has considerable promise for screening, early detection of recurrence and
evaluation of treatment response for a wide variety of carcinomas.
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The detection of circulating tumour cells (CTCs) in peripheral
blood was first suggested more than a century ago (Ashworth,
1869), but has only recently become a clinical reality. It is now
clear that cells are shed from tumours well before metastasis
(Liotta et al, 1974), and, therefore, that detection of CTCs could
provide a novel approach to screening, detection of recurrence and
evaluation of treatment response for many cancers (Cristofanilli
and Mendelsohn, 2006; Hayes et al, 2006; Cristofanilli et al, 2007).
Many methods have been proposed for the detection and
enumeration of CTCs including flow cytometry, nucleic acid-based
approaches and selective isolation followed by immunofluores-
cence microscopy (Baran et al, 1998; Racila et al, 1998;
Kowalewska et al, 2006; Pinzani et al, 2006).
We have developed a novel approach for the identification and
characterisation of CTCs based on a combination of antibody
fluorescence detection with fluorescence in situ hybridisation
(FISH), and the use of a fully automated fluorescence microscope
(Ntouroupi et al, 2007).
MATERIALS AND METHODS
Cell lines
The colorectal carcinoma (CRC) cell line C32 (Browning et al,
1993) and the prostate carcinoma cell line LNCaP (Horoszewicz
et al, 1983) were cultured as previously described. Other cell lines
were from the Cancer and Immunogenetics laboratory collection
(Liu and Bodmer, 2006). Cell counts were determined by a
Cellometer
s automatic cell counter (Nexcelom Bioscience,
Lawrence, MA, USA) and 5–1000 cells were spiked into donor
blood to estimate recovery yield. Alternatively, 1–3 cells were
micropipetted into blood. All spiking experiments were performed
in triplicate.
Blood samples
Blood samples were obtained from 10 biopsy-proven prostate
cancer patients, 25 colorectal cancer and 4 ovarian cancer patients.
In addition, blood was collected from seven individuals with
elevated serum prostate-specific antigen (PSA) levels but no
evidence of malignancy upon biopsy. Blood samples were collected
prior to, and within a few weeks of the pre-operative biopsy. The
blood samples collected from 11 healthy donors (age ranging from
21 to 71 years old) were used for spiking experiments and as
normal controls.
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participating in this study. Investigations were performed after
approval by the appropriate research ethical committee.
Isolation of CTCs by Lymphoprept
Whole blood was collected in acid citrate dextrose as antic-
oagulant, and the mononuclear cells, which included epithelial
cells, were separated by centrifuging through Lymphoprep (Ficoll-
Isopaque, Axis-Shield, Oslo, Norway). The resulting cell suspen-
sion (in phosphate buffer saline (PBS), pH 7 4) was deposited on
poly-L-lysine-coated, single-well chamber slides (IkoniSlide; Iko-
nisys Inc., New Haven, CT, USA) at a concentration of
approximately 8 10
5 cells per slide. The cells were then fixed
with ice-cold methanol for 5min followed by 2% formaldehyde in
PBS for 5min, washing with PBS (2 5min) and then with PBS-T
(0.05% Tween-20 in PBS).
Isolation of CTCs by filtration with track-etched
membranes
Blood was collected into acid citrate dextrose, diluted
into 10 volumes of 1  ammonium chloride-based lysing buffer
(BD Pharm Lyset) containing 0.5% formaldehyde and incubated
at room temperature (RT) for 15min. A Nucleopore (Whatman)
track-etched polycarbonate membrane filter (8.0mm pore size,
25mm diameter) was placed shiny side up in a reusable syringe
filter holder (PALL Life Sciences, Ann Arbor, MI, USA) and a
syringe barrel was used as a funnel (Seal, 1964; Song et al, 1971).
The use of a vacuum manifold (VM20; Sigma, St Louis, MO, USA)
allows processing of 20 samples simultaneously. Suction was
applied by a vacuum pump briefly at the beginning of the
filtration and then the sample was allowed to flow through by
gravity. The vacuum produced by the Misrosart
s maxi.vac pump
(Sartorius, Goettingen, Germany) can be monitored and con-
trolled, thereby allowing the collection of CTCs on the membrane
filter under optimal conditions. The diluted blood was filtered
through the Nucleopore membrane and washed with 100ml PBS.
The cells retained on the filter were fixed with ice-cold methanol
for 5min followed by 2% formaldehyde in PBS for 5min.
After washing with 100ml PBS, the filter was removed from the
filter holder and processed for antibody staining as described
below. This procedure allows fast and efficient isolation of
epithelial cells with minimum manipulation, thereby maintaining
cellular integrity.
Figure 1 Screen captures of the Viewer software that displays the data produced by the Ikoniscope
s scanning system (C). C32 cells were spiked in normal
blood, isolated by Lymphoprep
TM and immunostained with AUA1 and Cam5.2 followed by FISH with CEP probes for chromosomes 17 and 18. (A): High
magnification ( 100) target gallery screen showing composite images of C32 cells for AUA1 (Cy5), Cam5.2 (green) and nuclei (DAPI/blue) staining. (B):
Screenshot displaying a target C32 cell at high magnification. Pseudo colored images in the DAPI (nucleus), green (Cam5.2), Cy5 (AUA1), orange (CEP 17)
and aqua (CEP 18) channels are shown on the left side of the screen shot (clockwise from top left corner). A composite image of all five channels is shown at
the bottom right of the screen shot. After automatic identification of FISH signals, a pseudo colored composite image of the nucleus, in which chromosomes
17 appear in yellow and chromosomes 18 appear in aqua, is shown at the top right of the screenshot.
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All incubations were performed at RT, in humidified chambers,
protected from light. The cells were first incubated for 30min in
a blocking solution containing 0.01gml
 1 blocking reagent in
PBS-T (TSAt kit; Molecular Probes Inc.t, Eugene, OR, USA),
followed by 30min incubation with 2mgml
 1 AUA1 in blocking
solution. AUA1 is a mouse anti-EpCam monoclonal antibody
(Epenetos et al, 1982). For some prostate cancer patients, a mouse
monoclonal antibody against PSA (ER-PR8; Abcam, Cambridge,
MA, USA) was used at a concentration of 10mgml
 1 in blocking
solution. Specific binding was detected using HRP-conjugated goat
anti-mouse antibody (5mgml
 1 in blocking solution, 30min)
followed by green-fluorescent Alexa Fluor 488 tyramide labelling
according to the manufacturer’s protocol (TSA; Molecular Probes
Inc.). Peroxidase activity was quenched by incubating for 30min
with 2% H2O2 in PBS-T. After washing with PBS-T, the cells were
incubated for 30min with 7mgml
 1 of the biotinylated mouse
monoclonal antibody Cam5.2 against cytokeratins 7/8 (Makin et al,
1984). Specific binding was detected using HRP-conjugated
streptavidin (5mgml
 1 in blocking solution, 30min) followed by
labelling with far-red fluorescent Alexa Fluor 647 tyramide (which
is spectrally similar to Cy5). Specimens were coverslipped with
Vectashield mounting medium (Vector, Burlingame, CA, USA)
containing DAPI (40,6 0 diamidino-2-phenylindole), to preserve
fluorescence and counterstain the DNA. The use of the Tyramide
signal amplification detection method (Molecular Probes Inc.)
enables the combination of immunostaining with FISH, without
substantial loss of the antibody fluorescence signal intensity. The
fluorescent dye-labelled tyramide derivatives are activated by the
HRP conjugated to the secondary antibody and are covalently
coupled to nucleophilic residues in the vicinity of the HRP–target
interaction site. The tyramide signal amplification results in
increased sensitivity of detection and stronger signals. In addition,
the covalent nature of the binding of fluorescent dyes to targets
through tyramide renders the signals more stable and resistant to
the conditions the specimens are subjected to during FISH.
Fluorescence in situ hybridisation
Slides with positively immunolabelled cells on them were
dehydrated in ethanol series (50, 75 and 100% ethanol, 30s each),
air-dried at 371C for 15min and subsequently incubated at 371C
for 3min in a pre-warmed solution containing 0.001% pepsin and
10mM HCl. After washing with 50mM MgCl2 in PBS for 5min, cells
were fixed for 10min at RT with a solution of 2% formaldehyde
and 50mM MgCl2 in PBS. After washing in PBS (2 5min, RT) and
2  SSC (15min, 371C), the slides were dehydrated in ethanol
series and air-dried. Chromosome enumeration probes (CEP) for
chromosomes 7 (aqua), 8 (aqua), 17 (orange) and 18 (aqua) were
mixed with hybridisation buffer, and denaturation and hybridisa-
tion were performed according to the manufacturer’s instructions
(Vysis, Downers Grove, IL, USA). Following overnight hybridisa-
tion, the slides were washed in pre-warmed 0 4  SSC buffer with
0 3% NP-40 for 3min at 721C followed by 2min in 2  SSC with
0 1% NP-40 and 5min in 2  SSC. After air-drying for 2min, the
specimens were coverslipped with DAPI-containing Vectashield
mounting medium.
Robotic fluorescence microscopy
Identification and quantification of immunolabelled cells and FISH
analysis were performed using the Ikoniscope
s imaging system
(Kilpatrick et al, 2004; Evans et al, 2006; Ntouroupi et al, 2007).
The Ikoniscope robotic, high-throughput, image acquisition and
display microscopy system, is developed by Ikonisys for rare cell
identification and analysis. It uses epifluorescence optics manu-
factured by Olympus (Tokyo, Japan). Slides are fed to the
instrument through an automated slide/cassette feeder that
provides unattended handling of 175 slides. The microscope stage
is built for high speed and accuracy of slide movement in each of
the x, y and z directions. Image capture is performed through a
high-resolution and high-sensitivity monochrome charge-coupled
device camera (Hamamatsu Orca ER; Hamamatsu Photonic
Systems, Bridgewater, NJ, USA). Carefully controlled exposure
setting and automated focusing, combined with three-dimensional
image acquisition, are essential for rare cell detection. Cell
identification takes place in real time, using image analysis for
the detection and quantification of antibody and FISH signals.
Preparations are first scanned at low magnification ( 10) to
identify cells carrying both immunolabelled markers. Selected
target cells are then revisited at high magnification ( 100) for
verification and enumeration of FISH signals. Results are displayed
using the IkoniLAN
s viewer software that allows evaluation of
low-magnification images from all scanned fields as well as high-
magnification images of target cells in all fluorescence channels.
All stored information, raw images, processed images and
processing results are made available to the reviewers through
the IkoniLAN server both in local area computer networks as well
as wide area networks using the internet.
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Figure 2 Circulating tumour cells isolated by Lymphoprep from the
peripheral blood of colorectal and prostate cancer patients. Composite
pseudo colored images of cells at high magnification ( 100) in the DAPI,
green and Cy5 channels, are shown. (A) CTCs were isolated from
colorectal cancer patients Co 1, 2 and 9 and were immunostained with
AUA1 (green) and Cam5.2 (Cy5). (B) CTCs were isolated from prostate
cancer patients 1 and 2 and were immunostained with Cam5.2 (Cy5) and
AUA1 or PSA (green), as indicated.
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sRESULTS
Initial assay development was carried out using Lymphoprep
processing of normal blood samples spiked with known numbers
of cells from the CRC line C32 and other cell lines. Examples of
imaged cells from a spiking experiment are shown in Figure 1.
Mononuclear cells were deposited on slides, immunostained with
antibodies against EpCam (AUA1) and cytokeratins 7/8 (Cam5.2),
and FISH carried out for the enumeration of chromosomes 17 and
18, as described in Materials and Methods. Chromosomes 17 and
18 were chosen because C32 cells exhibit trisomy for 17 and are
diploid for 18 and therefore can be used to test the specificity
of detection by FISH. Between 90 and 100% of cells deposited
on slides were detected down to a dilution of one C32 cell
micropipetted into 8ml of blood and similar results were obtained
using the LNCaP prostate carcinoma cells. Figure 1 shows screen
captures of the Viewer software that displays the data produced by
the Ikoniscope scanning system (Figure 1C) (Kilpatrick et al, 2004;
Evans et al, 2006). Figure 1A shows a high magnification ( 100)
target gallery screen displaying images of identified C32 cells. The
displayed images are composites of the Cy5/red (AUA1), green
(Cam5.2) and DAPI (blue) channels. Figure 1B displays one of the
target C32 cells at high magnification ( 100). The three dots
corresponding to chromosomes 17 appear in yellow and the two
dots corresponding to chromosomes 18 appear in aqua, which fits
in with the known karyotype of C32 cells.
Representative cells identified in blood samples from colorectal
and prostate cancer patients, using Lymphoprep isolation and
antibody labelling, are shown in Figure 2. These demonstrate the
presence of very clearly identifiable doubly labelled epithelial, and
so presumptive tumour, cells in both sets of patients.
Spiking reconstruction experiments using the much simpler and
more rapid filter procedure, with a range of cell concentrations and
10 different cell lines, gave recoveries of 94–100% (data not
shown). This is consistent with measurements of the mean
diameters of cells from 20 different cancer cell lines, showing
that, on average, more than 90% cells had a mean diameter greater
than 8mm, which is the filter pore diameter (data not shown).
Representative cells identified from a colorectal and an ovarian
cancer patient as reacting with both the EpCam and cytokeratin
7/8 antibodies, and analysed by FISH for the enumeration of
chromosomes 7 and 8 are shown in Figure 3. Each cell is clearly
identified by reaction with both antibodies and has a definitely
abnormal chromosome count: seven dots for the colorectal and
eight dots for the ovarian cancer, compared with the four dots
expected. These cells are thus unequivocally identified as CTCs
with a readily recognisable morphology. The choice of these
particular chromosomes was based on a database search, which
showed high incidence of polysomies for chromosomes 7 and 8
in colorectal, prostate and ovarian cancer cell lines and
patient cases (http://www.cgap.nci.nih.gov/Chromosomes/Mitelman,
http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi).
No cells reacting with both antibodies to EpCam and
cytokeratins7/8 have been found in any of the four (two females,
two males) Lymphoprep and seven (three females and four males)
filter-prepared healthy control samples (Table 1).
A summary of data obtained so far on 25 colorectal, 10 prostate
and 4 ovarian cancer patients is shown in Table 1. Presumptive
CTCs were not detected in only 2 out of 25 CRC patients, 1 of
whom had no nodal involvement. The mean number of CTCs per
millilitre was slightly lower (1.6) for the Lymphoprep than for the
filter-isolated (2.2) samples.
In all 10 prostate cancer patients analysed, CTCs were detected.
Among the seven men who presented with elevated PSA levels but
had no evidence of malignancy upon biopsy, four had no
detectable CTCs. In the remaining three cases, where the biopsy
indicated no malignancy, CTCs were detected (1.4–1.7cellsml
 1)
strongly suggesting that these patients should be reinvestigated, or
at least carefully followed up. It should be noted that in all three of
the above-mentioned cases, the identified cells were positive for
PSA as well as for AUA1 and Cam5.2. These data, although clearly
very preliminary, suggest that the Ikoniscope based CTC detection
may be an effective way to reduce the number of false-positives for
prostate malignancy based on elevated PSA levels. All four ovarian
Ov 4 Co 11
Composite
image
CEP 7 & 8
aqua Dot count
Composite
image
CEP 7 & 8
aqua Dot count
Figure 3 Circulating tumour cells isolated by filtration from the peripheral blood of colorectal and ovarian cancer patients. Composite pseudo colored images of
cells at high magnification ( 100) in the DAPI, green, Cy5 and aqua channels are shown on the left of each panel, followed by cell images in the aqua
channel in the middle of each panel. After automatic identification of FISH signals (dot count), a pseudo colored composite image of the nucleus, in which
chromosomes 7 and 8 appear in aqua, is shown on the right of each panel. (A) CTCs were isolated from colorectal cancer patient Co 11 and were
immunostained with AUA1 (green) and Cam5.2 (Cy5), followed by FISH with CEP 7/aqua and CEP 8/aqua. A total of 7 aqua dots are present in each
nucleus, indicating polysomy for at least one of the chromosomes 7 and 8. (B) CTCs were isolated from ovarian cancer patient Ov 4 and were
immunostained with AUA1 (green) and Cam5.2 (Cy5), followed by FISH with CEP 7/aqua and CEP 8/aqua. A total of 8 aqua dots are present in each
nucleus, indicating polysomy for at least one of the chromosomes 7 and 8.
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by patient/control group, indicating the percentage of positive
samples as well as the range, mean and median number of CTCs
detected per millilitre of blood.
Five patients (three CRCs, two ovarian) were analysed by FISH
for chromosomes 7 and 8 combined (see Figure 3) and all had
significantly more than four dots per cell.
DISCUSSION
We have shown that the Ikoniscope based automated fluorescence
microscopy can readily detect less than one circulating epithelial
cell per millilitre of blood. The use of two different epithelial-
specific antibodies, against EpCam and cytokeratin 7/8, makes it
most probable that cells, which label with both antibodies, are
indeed CTCs. This has been confirmed in those cases where FISH
has shown clear-cut chromosomal abnormality, and is made very
likely by the fact that no doubly labelled cells were seen in any of
Table 1 Detection of CTCs in control samples and in colorectal, prostate and ovarian cancer patients
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Abbreviation: PSA¼prostate specific antigen.
Table 2 Summary of results for CTC detection in all sample groups
CTC positive
Cells per ml blood
Sample group nn (%) Range Mean Median
Colorectal 25 23 (92) 0–10.2 1.96 0.9
Prostate 10 10 (100) 0.3–9.4 3.99 3.6
Ovarian 4 4 (100) 0.5–1.9 0.98 0.75
Elevated PSA/NEM 7 3 (42.9) 0–1.7 0.64 0
Healthy controls 11 0 (0) 0 0 0
Abbreviations: PSA¼prostate specific antigen; NEM¼no evidence of malignancy
upon biopsy.
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sensitive and allows the combination of different antibodies and
additional downstream analyses (FISH, and so on). The isolation
procedure could easily be at least partially automated. Sample
manipulation is minimal and the isolation is fast and simple,
thereby minimising cell loss and preserving cellular morphology. It
also enables all the cells from a 10ml sample of blood to be
deposited on a single slide, which greatly reduces the overall
preparation time and cost as well as the microscope scanning time.
Currently, the time to scan one slide at both low and high
magnification is about 1h, but in future this will be substan-
tially reduced by anticipated improvements of the Ikoniscope
technology. Detection of CTCs by simply counting the cells
retained on the filters, as has been proposed (Song et al, 1971;
Pinzani et al, 2006), is clearly not adequate, but when combined
with automated immunofluorescence and FISH, identification
becomes a highly efficient procedure. The particular advantage of
our automated detection system is the ability to image morpho-
logically clearly identifiable cells, which are characterised by both
two epithelial-specific antibodies and FISH to detect chromosomal
abnormalities, which are a hallmark of most carcinomas.
There are many obvious developments of the procedure we have
described. In our study, we used a combination of immunostaining
with AUA1/PSA and Cam5.2 followed by FISH for chromosomes 7
and 8 for the identification of CTCs. Future plans including the use
of additional antibodies, for example, against p53, MUC-1, the
mismatch repair proteins hMLH1 and hMSH2, or cell cycle-
specific proteins, may help to define the circulating cells
unequivocally as tumour cells even without the need to do FISH.
Some antibodies, such as those against cleaved caspase 3 for
apoptosis, or against phosphotyrosine residues on signalling
proteins, may provide new approaches to non-invasive assessment
of response to therapy. Increasing the number of chromosomes
that are simultaneously identified by FISH will also help to
establish their tumorigenic phenotype. Fluorescence in situ
hybridisation can also be used to determine HER2, EGFR and
other gene amplifications. Eventually, it should be possible to
isolate the individual CTCs by, for example, laser microdissection,
and then do a more or less comprehensive genetic and gene
expression analysis on the isolated cells. The detection strategy
may also be used for other sources of cells, for example, from bone
marrow, sputum, urine, breast nipple aspirates, lymph nodes or
colonic washings.
There are at least three clearly different types of applications for
the detection of CTCs. (i) Screening for early detection of cancer.
This is probably the most demanding and may often follow on
from a cheaper, more high-throughput initial screen, for example,
PSA and related tests for prostate cancer, or faecal occult blood for
colorectal cancer. However, in the case of ovarian cancer, where so
far there has been no satisfactory initial high-throughput screening
test, detection of CTCs may well satisfy the needs for a primary
screen, perhaps first evaluated in high-risk cases. (ii) Detection of
recurrence, where the key is whether the presence of detectable
CTCs provides a significant time advantage over other approaches
to clinical diagnosis. (iii) Evaluation of response to therapy.
In situations where the aim of CTC detection is to determine
whether to proceed with more invasive diagnostic procedures,
simply identifying the presence of unexpected epithelial cells in
blood may be sufficient. More extensive characterisation of
potential cancer cells can then be carried out on biopsy material.
The aim of the present study was to establish proof of principle
by analysing relatively small numbers of patient samples from
three different cancer types (colorectal, prostate and ovarian). The
next step is to study the clinical relevance and utility of our
approach to the detection of CTCs, by analysing samples from a
large and defined patient cohort.
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